Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $125.65

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has received an average recommendation of “Moderate Buy” from the twenty-three brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and twenty have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $125.6522.

Several equities analysts have recently commented on KYMR shares. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Friday, July 17th. Oppenheimer reiterated an “outperform” rating and set a $125.00 price objective on shares of Kymera Therapeutics in a report on Wednesday, August 5th. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Royal Bank Of Canada downgraded Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and boosted their target price for the company from $106.00 to $115.00 in a research note on Monday, July 13th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $134.00 target price on shares of Kymera Therapeutics in a research report on Thursday, June 25th.

Insiders Place Their Bets

In related news, Director Bruce Booth sold 31,283 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $109.48, for a total value of $3,424,862.84. Following the completion of the sale, the director owned 461,794 shares of the company’s stock, valued at approximately $50,557,207.12. The trade was a 6.34% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Bruce N. Jacobs sold 77,109 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total value of $8,864,450.64. Following the completion of the transaction, the chief financial officer owned 244,883 shares in the company, valued at $28,151,749.68. This represents a 23.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,604,813 shares of company stock worth $387,557,004 in the last quarter. Corporate insiders own 15.98% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of KYMR. Smartleaf Asset Management LLC raised its holdings in shares of Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC lifted its stake in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after purchasing an additional 98 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Kymera Therapeutics during the fourth quarter worth $63,000.

Kymera Therapeutics Stock Performance

KYMR stock opened at $119.80 on Friday. The stock has a market cap of $9.96 billion, a P/E ratio of -36.98 and a beta of 1.95. The firm has a 50 day simple moving average of $109.42 and a 200 day simple moving average of $92.15. Kymera Therapeutics has a 52 week low of $39.84 and a 52 week high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The firm had revenue of $65.00 million for the quarter, compared to analyst estimates of $32.78 million. During the same quarter in the prior year, the business earned ($0.95) EPS. The company’s revenue for the quarter was up 465.2% compared to the same quarter last year. Sell-side analysts predict that Kymera Therapeutics will post -3.75 EPS for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.